News · Research
The latest in peptide research
Newly published studies and clinical trials, explained plainly and linked to their source. Informing is part of the lab, too.
Loading the latest publications…
Human studyWeekly semaglutide: 14.9% weight loss in the STEP 1 trial
In adults with overweight or obesity without diabetes, weight loss was sustained and clinically relevant versus placebo.
Read the noteHuman studySELECT: semaglutide reduced cardiovascular events in people without diabetes
17,604 participants with prior cardiovascular disease and overweight or obesity, followed for almost 40 months.
Read the noteHuman studyFLOW: semaglutide protected the kidney in type 2 diabetes with kidney disease
The risk of the combined kidney and cardiovascular outcome was 24% lower than with placebo.
Read the noteHuman studyESSENCE: semaglutide improved liver histology in fatty liver with inflammation
Phase 3 in 1,197 people with metabolic steatohepatitis and moderate or advanced fibrosis confirmed by biopsy.
Read the noteHuman studyHeart failure and obesity: semaglutide improved symptoms and physical capacity
In STEP-HFpEF, symptoms, physical limitation and walking distance improved versus placebo.
Read the noteHuman studySURMOUNT-1: tirzepatide achieved substantial, sustained weight reductions
A 72-week trial in people with obesity testing three weekly doses against placebo.
Read the noteHuman studySleep apnoea: tirzepatide reduced night-time breathing pauses
Two phase 3 trials in adults with moderate-to-severe obstructive sleep apnoea and obesity.
Read the noteHuman studySUMMIT: tirzepatide lowered the risk of worsening heart failure
Fewer cardiovascular deaths or heart-failure worsening events than placebo, and better health status.
Read the noteHuman studyHead to head: tirzepatide beat semaglutide on weight loss
SURMOUNT-5 compared both peptides directly in 751 adults with obesity without diabetes over 72 weeks.
Read the noteHuman studyRetatrutide, the triple agonist, showed large weight loss in phase 2
It acts on GIP, GLP-1 and glucagon receptors at once; the effect was dose-dependent at 48 weeks.
Read the noteHuman studyType 2 diabetes: retatrutide cut HbA1c by up to 2.2 points in 36 weeks
In phase 2 it outperformed placebo and dulaglutide on glucose control, with weight loss of up to 16.9%.
Read the noteHuman studyRetatrutide's first phase 3 trial: better glucose and up to 15.3% less weight
TRANSCEND-T2D-1, published in June 2026 in The Lancet, with 537 people with type 2 diabetes.
Read the noteHuman studyFatty liver: with retatrutide, 86% normalised their liver fat
Phase 2a substudy in Nature Medicine: liver fat fell by more than 80% at higher doses in 24 weeks.
Read the note
Human studyTesamorelin reduced liver fat and halted fibrosis in people with HIV
A 12-month randomised trial of the GHRH analogue in HIV-associated fatty liver.
Read the note
Human studyBremelanotide improved sexual desire in two phase 3 trials
The RECONNECT studies evaluated this melanocortin agonist in premenopausal women with hypoactive sexual desire.
Read the noteHuman studyKisspeptin triggered egg maturation in in-vitro fertilisation
A pioneering study showed this natural peptide can replace the classic hormonal trigger in IVF.
Read the note
PublicationFDA approved elamipretide (SS-31), the first treatment for Barth syndrome
Accelerated approval for a peptide that acts in the mitochondria, in a rare and serious disease.
Read the noteAnimal studyMOTS-c, the peptide exercise produces, improved physical capacity in old mice
In Nature Communications: treatment started late in life increased physical capacity in old mice.
Read the noteReviewGHK-Cu: the review that gathered its regenerative effects on skin
The copper tripeptide stimulates collagen, elastin and fibroblast function, according to the data reviewed.
Read the note
Human studyARA-290 (cibinetide) improved neuropathic pain and regrew nerve fibres
In people with sarcoidosis and small-fibre nerve damage, 28 days of treatment beat placebo.
Read the note
Human studyLL-37 cream sped up healing of diabetic foot ulcers
A randomised, double-blind trial with the antimicrobial peptide the body makes itself.
Read the noteHuman studyIntravenous BPC-157 was well tolerated in a first pilot study
A very small pilot, in two healthy adults, found no adverse effects or changes in organ markers.
Read the noteReviewThymosin alpha-1: over 11,000 people in trials support its profile
A review of more than 30 clinical trials describes it as a well-tolerated immune modulator.
Read the note